Marker Therapeutics (MRKR) Issues Clinical and Pipeline Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Marker Therapeutics (MRKR) Issues Clinical and Pipeline Update

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

February 16, 2022 4:30 PM EST

Results from safety lead-in stage of Markers Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading

New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time

Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023

Company to host conference... More